ArticleJournal of pharmaceutical health care and sciences2022

Casirivimab-imdevimab neutralizing SARS-CoV-2: post-infusion clinical events and their risk factors.

Junichi Yoshida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.